DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Regavirumab
Regavirumab
(12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al
Inclusion and Exclusion Criteria for Each Key Question
(12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng Et Al
WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
The Two Tontti Tudiul Lui Hi Ha Unit
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
(INN) for Biological and Biotechnological Substances
The Growth and Potential of Human Antiviral Monoclonal Antibody Therapeutics
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
Ep 2966085 A1
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
A61K9/51 (2006.01) — with International Search Report (Art
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Assessment of the Evolution of Cancer Treatment Therapies
Top View
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
La Merie Publishing
Customs Tariff - Schedule Xxi - 1
Tim Malawi Mai Multe
Fig. 2 O W O 2012/149282 A2 1Inn Iiiiiii 1Mil I Mil Il I 1Ill I Mil I Il I I Mill Mi I I
Avastin, INN-Bevacizumab
(12) United States Patent (10) Patent No.: US 8,846,044 B2 Maggio (45) Date of Patent: *Sep
INN-Nimet 1 27.11.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(12) Patent Application Publication (10) Pub. No.: US 2015/0010548 A1 Jesek Et Al
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Harmonized Tariff Schedule of the United States (2006) (Rev
Assessment of the Evolution of Cancer Treatment Therapies
Supplemental Table 1: Inclusion and Exclusion Criteria
WHO Drug Information Vol. 12, No. 4, 1998
INN-Nimet 1 1.7.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara